Joshua Resnick - 22 May 2025 Form 4 Insider Report for Vor Biopharma Inc. (VOR)

Reporting relationship: Director
Issuer ticker: VOR
Reported as of: 22 May 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 May 2025, 17:45:40 UTC
Prior SEC filing: 06 Feb 2025
Next SEC filing: 06 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Katie Kazem, Attorney-in-Fact

Key filing fact

Joshua Resnick filed Form 4 for Vor Biopharma Inc. (VOR) on 23 May 2025.

Key facts

This page summarizes Joshua Resnick's Form 4 filing for Vor Biopharma Inc. (VOR).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 23 May 2025, 17:45.

Change

Previous filing in this sequence was filed on 06 Feb 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001690959 Primary reporting owner

Resnick Joshua

Relationship: Director
Address: C/O VOR BIOPHARMA INC., 100 CAMBRIDGEPARK DRIVE, SUITE 101, CAMBRIDGE
Signature: /s/ Katie Kazem, Attorney-in-Fact
Signature date: 23 May 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VOR transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +30,000
Change %
Price: $0.000000
Shares after: 30,000
Date: 22 May 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 30,000
Exercise price: $0.1868
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) May 22, 2026 or (ii) the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date.

Footnote F2

Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund") and the RA Capital Nexus Fund, L.P. (the "Nexus Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option, which will offset advisory fees owed by the Fund and the Nexus Fund to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.